RPG Life Sciences is making significant strides in the pharmaceutical sector by investing ₹215 crore in two active pharmaceutical ingredient (API) manufacturers within a mere five weeks. This rapid acquisition strategy marks a notable shift for a company historically cautious with its capital expenditures.
However, RPG Life Sciences is not stopping there. The company has earmarked an additional ₹700 crore for future acquisitions, signaling its intent to pursue larger targets in the API space.
Strategic Shift in Global Sourcing
The driving force behind this aggressive expansion is the changing landscape of global pharmaceutical sourcing. According to managing director Ashok Nair, the discourse has evolved from a binary choice between India and China to a more nuanced approach. Customers are increasingly seeking diversification in their supply chains to mitigate risks, a trend encapsulated in the ‘China plus one’ strategy. Nair emphasizes that India is uniquely positioned to capitalize on this shift, supported by favorable government incentives.
By moving towards backward integration in key ingredients, RPG aims to secure long-term contracts and solidify its status as a trusted supplier for various APIs. This strategic pivot signifies a commitment to enhance its operational framework while maintaining cost efficiency.
Growth Trajectory and Future Aspirations
Under the stewardship of Nair, RPG Life Sciences has transitioned from a cautious approach to one marked by conviction and urgency. The company has experienced impressive growth, expanding its revenue from ₹200 crore to ₹700 crore over the past five years. Nair has set an ambitious target to reach ₹1,000 crore soon, with inorganic growth being a central component of this strategy. Since taking charge 14 months ago, he has accelerated the pace of acquisitions, reflecting a heightened appetite for expansion.
The establishment of G Active Pharma (RPGAP) in late July represents a pivotal moment for RPG’s API operations. Partnering with healthcare private equity firm InvAscent, which has invested ₹243 crore for a 40% stake, RPGAP has committed a total of ₹700 crore primarily for acquisitions.
Recent Acquisitions and Capacity Expansion
RPGAP’s acquisition spree began with the purchase of ActisGenerics, based in Visakhapatnam, for ₹80 crore. Just five weeks later, RPGAP signed an agreement to acquire the API and intermediates business of Raghava Life Sciences for up to ₹135 crore. This strategic move adds an EU-GMP- and WHO-GMP-approved plant near Hyderabad, along with 29 new molecules. Collectively, these acquisitions have increased RPGAP’s production capacity nearly fivefold, from approximately 110 kilolitres to around 505 kilolitres.
The synergies between the two acquired companies are noteworthy. ActisGenerics specializes in intermediates for complex molecules, while Raghava focuses on finished APIs. Nair emphasizes that this backward integration enhances the value proposition, marking a deliberate strategy to deepen the company’s expertise in the chemistry chain rather than merely increasing volume.
Niche Opportunities in the API Market
Nair believes that the API sector presents unique opportunities, as it remains less crowded compared to finished formulations. He points to the complexity of synthesizing certain APIs, such as rivaroxaban, which involves a 17-step process. This complexity serves as a barrier to entry, limiting competition and supporting higher prices compared to more straightforward formulation processes. The Indian API market is estimated to exceed ₹1 trillion, with an annual growth rate of approximately 8%. India’s status as the third-largest global producer is bolstered by government initiatives like the production-linked incentive (PLI) scheme.
Analyst Perspectives and Future Outlook
The market has responded positively to RPG’s strategic moves. ICICI Securities has rated the stock as a ‘Buy,’ projecting a 12-month target of ₹3,205, representing a potential 20% increase from current levels. Analyst Siddhant Khandekar highlights that these acquisitions position APIs as a vital growth driver with substantial room for value creation.
Looking ahead, Khandekar anticipates further deals in the API sector. Despite Raghava’s plant generating approximately ₹19 crore last year, its potential could rise to nearly ₹200 crore if fully utilized. However, Khandekar also notes that delays in integrating new API businesses pose a risk, especially since the combined revenue of the two acquired units was around ₹70 crore last year.
A Calculated Approach to Future Acquisitions
While RPG Life Sciences has made significant investments, Nair remains cautious about future expenditures. He notes that the company still has a reserve of ₹500 to ₹700 crore for potential acquisitions, particularly targeting larger assets, including those with USFDA approval. Nair is committed to maintaining valuation discipline as RPG aims to develop a multi-site API company with expertise in chemistry, manufacturing, product approval, R&D, and customer relations.
In conclusion, RPG Life Sciences is strategically positioning itself to thrive in the evolving pharmaceutical landscape. By focusing on API acquisitions and embracing the ‘China plus one’ strategy, the company is poised for significant growth. As it continues to expand its capabilities and explore new opportunities, RPG Life Sciences is transforming into a formidable player in the global pharmaceutical arena.
- RPG Life Sciences has invested ₹215 crore in two API acquisitions.
- The company aims to secure an additional ₹700 crore for future growth.
- RPGAP’s recent acquisitions have nearly quintupled its production capacity.
- The Indian API market is projected to exceed ₹1 trillion, growing at 8% annually.
- Analysts predict more acquisitions in the API sector and a positive outlook for RPG’s stock.
Read more → www.livemint.com